Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology
Open accessThe DOI matches its Crossref record; 273 of the 273 references it cites were found in a registry or an index.
Abstract
These British Association for Psychopharmacology guidelines cover the range and aims of treatment for anxiety disorders. They are based explicitly on the available evidence and are presented as recommendations to aid clinical decision making in primary and secondary medical care. They may also serve as a source of information for patients and their carers. The recommendations are presented together with a more detailed review of the available evidence. A consensus meeting involving experts in anxiety disorders reviewed the main subject areas and considered the strength of evidence and its clinical implications. The guidelines were constructed after extensive feedback from participants and interested parties. The strength of supporting evidence for recommendations was rated. The guidelines cover the diagnosis of anxiety disorders and key steps in clinical management, including acute treatment, relapse prevention and approaches for patients who do not respond to first-line treatments.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This is in line with the clinical observation that specific phobias respond less well to treatments such as citalopram than other pathological anxiety states (Baldwin et al, 2005) and with preclinical evidence in rodents showing that the serotonergic system may not be critical for the expression of phasic fear-potentiated startle (Davis et al, 1988).”
From Phasic vs Sustained Fear in Rats and Humans: Role of the Extended Amygdala in Fear vs Anxiety (2010) · cites this paper as Baldwin et al, 2005
Citations
Cites
1 retracted
Antidepressants for generalised anxiety disorder (GAD)
Kapczinski, F., dos Santos Souza, J. J., Batista Miralha da Cunha, A. A., & Schmitt, R. R. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003592 · Cited by 162
RetractedDiagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
The Hospital Anxiety and Depression Scale
Zigmond, A. S., & Snaith, R. P. (1983) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1983.tb09716.x · Cited by 47,139
Kessler, R. C. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950010008002 · Cited by 12,370
Self-citationPosttraumatic Stress Disorder in the National Comorbidity Survey
Kessler, R. C. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950240066012 · Cited by 10,379
The validity of the Hospital Anxiety and Depression Scale
Bjelland, I., Dahl, A. A., Haug, T. T., & Neckelmann, D. (2002) · Journal of Psychosomatic Research · doi:10.1016/s0022-3999(01)00296-3 · Cited by 9,779 · cited 2×
“Screening questions and self-report questionnaires are fairly sensitive but not very specific, making the value of routine screening for anxiety disorders questionable (Goldberg and Bridges, 1987; Dowell et al., 1990; Lewis and Wessely, 1990; Parkerson and Broadhead, 1997; Wittchen and Boyer, 1998; Bjelland et al., 20…”
BackgroundPrevalence and development of psychiatric disorders in childhood and adolescence
Costello, E. J., Mustillo, S., Erkanli, A., Keeler, G., & Angold, A. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.8.837 · Cited by 4,035
The National Institute for Clinical Excellence
(2001) · Nursing Management · doi:10.7748/nm.8.2.39.s15 · Cited by 3,876
Size and burden of mental disorders in Europe—a critical review and appraisal of 27 studies
Wittchen, H.-U., & Jacobi, F. (2005) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2005.04.012 · Cited by 1,503
The economic burden of anxiety disorders in the 1990s
Greenberg, P. E., Sisitsky, T., Kessler, R. C., Finkelstein, S. N., Berndt, E. R., Davidson, J. R. T., Ballenger, J. C., & Fyer, A. J. (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n0702 · Cited by 1,242 · cited 1×
“Anxiety disorders are associated with a substantial economic burden, both for the health system and (especially) for the wider society in terms of productivity losses (I) (Souetre et al., 1994; Salvador-Carulla et al., 1995; Rice and Miller, 1998; Greenberg et al., 1999; Andlin-Sobocki & Wittchen, 2005), but there hav…”
BackgroundSelf-citationDiagnostic and Statistical Manual of Mental Disorders
(2018) · The SAGE Encyclopedia of Educational Research, Measurement, and Evaluation · doi:10.4135/9781506326139.n198 · Cited by 1,230
Clinical guidelines: Developing guidelines
Shekelle, P. G., Woolf, S. H., Eccles, M., & Grimshaw, J. (1999) · BMJ · doi:10.1136/bmj.318.7183.593 · Cited by 1,222
Foa, E. B., Liebowitz, M. R., Kozak, M. J., Davies, S., Campeas, R., Franklin, M. E., Huppert, J. D., Kjernisted, K., Rowan, V., Schmidt, A. B., et al. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.1.151 · Cited by 1,048
Prospective Study of Posttraumatic Stress Disorder and Depression Following Trauma
Shalev, A. Y., Freedman, S., Peri, T., Brandes, D., Sahar, T., Orr, S. P., & Pitman, R. K. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.5.630 · Cited by 996
Pilot study of secondary prevention of posttraumatic stress disorder with propranolol
Pitman, R. K., Sanders, K. M., Zusman, R. M., Healy, A. R., Cheema, F., Lasko, N. B., Cahill, L., & Orr, S. P. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01279-3 · Cited by 964
Barlow, D. H., Gorman, J. M., Shear, M. K., & Woods, S. W. (2000) · JAMA · doi:10.1001/jama.283.19.2529 · Cited by 953
Anderson, I., Ferrier, I., Baldwin, R., Cowen, P., Howard, L., Lewis, G., Matthews, K., McAllister-Williams, R., Peveler, R., Scott, J., et al. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881107088441 · Cited by 908
Self-citationBandelow, B., Zohar, J., Hollander, E., Kasper, S., Möller, H.-J., WFSBP TASK FORCE ON TREATMENT GUIDE, Bandelow, B., Zohar, J., Hollander, E., Kasper, S., et al. (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970802465807 · Cited by 854
Self-citationThe Cross National Epidemiology of obsessive-compulsive disorder
Weisman, M. M., Bland, R. C., CANINO, G. J., Greenwald, S., Hwu, H., Lee, C. K., Newman, S. C., Browne, M. A. O., Rubio-Stipec, M., WICKRAMARATNE, P. J., et al. (1994) · Max Planck Institute for Plasma Physics · Cited by 688
Compulsive buying: descriptive characteristics and psychiatric comorbidity.
Ga, C., Faber, R., de Zwaan, M., Raymond, N. C., Sm, S., Ekern, Tb, M., Crosby, R. D., Sj, C., & Ed, E. (1994) · PubMed · Cited by 664
Weissman, M. M., Bland, R. C., CANINO, G. J., Greenwald, S., Hwu, H., Lee, C. K., Newman, S. C., Oakley‐Browne, M., Rubio-Stipec, M., & WICKRAMARATNE, P. J. (1994) · PubMed · Cited by 648
Past-Year Use of Outpatient Services for Psychiatric Problems in the National Comorbidity Survey
Kessler, R. C., Zhao, S., Katz, S. J., Kouzis, A. C., Frank, R. G., Edlund, M., & Leaf, P. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.1.115 · Cited by 610
Cognitive Behavioral Group Therapy vs Phenelzine Therapy for Social Phobia: 12-Week Outcome
Heimberg, R. G., Liebowitz, M. R., Hope, D. A., Schneier, F. R., Holt, C. S., Welkowitz, L. A., Juster, H. R., Campeas, R., Bruch, M. A., Cloitre, M., et al. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.12.1133 · Cited by 585
McDougle, C. J., Epperson, C. N., Pelton, G. H., Wasylink, S., & Price, L. H. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.8.794 · Cited by 571
McDougle, C. J. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950040046006 · Cited by 570
Clark, D. M., Ehlers, A., McManus, F., Hackmann, A., Fennell, M., Campbell, H., Flower, T., Davenport, C., & Louis, B. (2003) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.71.6.1058 · Cited by 561
McGlashan, T. H., Grilo, C. M., Skodol, A. E., Gunderson, J. G., Shea, M. T., Morey, L. C., Zanarini, M. C., & Stout, R. L. (2000) · Acta Psychiatrica Scandinavica · doi:10.1034/j.1600-0447.2000.102004256.x · Cited by 542 · cited 1×
“Treatments with unproven efficacy in GAD include the beta-blocker propranolol (Ib) (Meibach et al., 1987).”
BackgroundSartorius, N., Üstün, T. B., Lecrubier, Y., & Wittchen, H.-U. (1996) · British Journal of Psychiatry · doi:10.1192/s0007125000298395 · Cited by 541 · cited 1×
“Comorbidity of anxiety with depression improves the detection of mental health problems (Sartorius et al., 1996; Wittchen et al., 2002).”
Background(2002) · PubMed · Cited by 518
Proudfoot, J., Ryden, C., Everitt, B., Shapiro, D. A., Goldberg, D., Mann, A., Tylee, A., Marks, I., & Gray, J. A. (2004) · British Journal of Psychiatry · doi:10.1192/bjp.185.1.46 · Cited by 516
Haynes, R. B., Devereaux, P. J., & Guyatt, G. H. (2002) · BMJ · doi:10.1136/bmj.324.7350.1350 · Cited by 510
Immediate treatment with propranolol decreases posttraumatic stress disorder two months after trauma
Vaiva, G., Ducrocq, F., Jezequel, K., Averland, B., Lestavel, P., Brunet, A., & Marmar, C. R. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00412-8 · Cited by 499 · cited 1×
“, 2002), and a naturalistic study suggests acute administration of propranolol (120 mg/day) prevented the emergence of syndromal PTSD at two months (IIa) (Vaiva et al., 2003).”
BackgroundAcute Pain Management: Operative or Medical Procedures and Trauma
Follin, S. L., & Charland, S. L. (1997) · Annals of Pharmacotherapy · doi:10.1177/106002809703100917 · Cited by 489
Long-term Electrical Capsular Stimulation in Patients with Obsessive-Compulsive Disorder
Nuttin, B. J., Gabriëls, L. A., Cosyns, P. R., Meyerson, B. A., Andréewitch, S., Sunaert, S. G., Maes, A. F., Dupont, P. J., Gybels, J. M., Gielen, F., et al. (2003) · Neurosurgery · doi:10.1227/01.neu.0000064565.49299.9a · Cited by 487
Kessler, R. C., DuPont, R. L., Berglund, P., & Wittchen, H.-U. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.12.1915 · Cited by 486
Ehlers, A., Clark, D. M., Hackmann, A., McManus, F., Fennell, M., Herbert, C., & Mayou, R. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.10.1024 · Cited by 485
(1998) · PubMed · Cited by 460
Self-citationWhy do people with anxiety disorders become depressed? A prospective‐longitudinal community study
Wittchen, H., Kessler, R. C., Pfister, H., Höfler, M., & Lieb, R. (2000) · Acta Psychiatrica Scandinavica · doi:10.1111/j.0065-1591.2000.acp29-03.x · Cited by 458
Roy-Byrne, P. P., Stang, P., Wittchen, H.-U., Ustun, B., Walters, E. E., & Kessler, R. C. (2000) · British Journal of Psychiatry · doi:10.1192/bjp.176.3.229 · Cited by 446
Nulman, I., Rovet, J., Stewart, D. E., Wolpin, J., Pace-Asciak, P., Shuhaiber, S., & Koren, G. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.11.1889 · Cited by 441
Which SSRI? A Meta-Analysis of Pharmacotherapy Trials in Pediatric Obsessive-Compulsive Disorder
Geller, D. A., Biederman, J., Stewart, S. E., Mullin, B., Martin, A., Spencer, T., & Faraone, S. V. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.11.1919 · Cited by 434
Fluoxetine, Comprehensive Cognitive Behavioral Therapy, and Placeboin Generalized Social Phobia
Davidson, J. R. T., Foa, E. B., Huppert, J. D., Keefe, F. J., Franklin, M. E., Compton, J. S., Zhao, N., Connor, K. M., Lynch, T. R., & Gadde, K. M. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.10.1005 · Cited by 415
Self-citationTyrer, P., & Baldwin, D. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69865-6 · Cited by 404
Self-citationSocial Phobia Subtypes in the National Comorbidity Survey
Kessler, R. C., Stein, M. B., & Berglund, P. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.5.613 · Cited by 398
Epidemiology and comorbidity of anxiety disorders in the elderly
(1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.5.640 · Cited by 396
Goodwin, G. M. (2003) · Journal of Psychopharmacology · doi:10.1177/0269881103017002003 · Cited by 390
Recognition, Management, and Course of Anxiety and Depression in General Practice
Ormel, J. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810320024004 · Cited by 375
Size and burden of social phobia in Europe
Fehm, L., Pelissolo, A., Furmark, T., & Wittchen, H.-U. (2005) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2005.04.002 · Cited by 373
McCrone, P., Knapp, M., Proudfoot, J., Ryden, C., Cavanagh, K., Shapiro, D. A., Ilson, S., Gray, J. A., Goldberg, D., Mann, A., et al. (2004) · British Journal of Psychiatry · doi:10.1192/bjp.185.1.55 · Cited by 371
Self-citationGould, R. A., Otto, M. W., Pollack, M. H., & Yap, L. (1997) · Behavior Therapy · doi:10.1016/s0005-7894(97)80048-2 · Cited by 352
Cognitive-behavioral therapy for social anxiety disorder: Current status and future directions
Heimberg, R. G. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01183-0 · Cited by 351
Stein, M. B., Kline, N. A., & Matloff, J. L. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.10.1777 · Cited by 347
Schelling, G., Kilger, E., Roozendaal, B., de Quervain, D. J.-F., Briegel, J., Dagge, A., Rothenhäusler, H.-B., Krauseneck, T., Nollert, G., & Kapfhammer, H.-P. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2003.09.014 · Cited by 345
Schelling, G., Briegel, J., Roozendaal, B., Stoll, C., Rothenhäusler, H.-B., & Kapfhammer, H.-P. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01270-7 · Cited by 337
Evidence-based pharmacotherapy of obsessive-compulsive disorder
Fineberg, N. A., Brown, A., Reghunandanan, S., & Pampaloni, I. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711001829 · Cited by 336
Self-citationLong-term Therapeutic Use of Benzodiazepines: I. Effects of Abrupt Discontinuation
Rickels, K. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810220015002 · Cited by 332 · cited 1×
“Discontinuation symptoms have their peak severity at two days for short half-life and 4–7 days for long-half life benzodiazepines (Rickels et al., 1990).”
BackgroundPooled Analysis of Antidepressant Levels in Lactating Mothers, Breast Milk, and Nursing Infants
Weissman, A. M., Levy, B. T., Hartz, A. J., Bentler, S., Donohue, M., Ellingrod, V. L., & Wisner, K. L. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.6.1066 · Cited by 329
Comparison of Aerobic Exercise, Clomipramine, and Placebo in the Treatment of Panic Disorder
Broocks, A., Bandelow, B., Pekrun, G., George, A., Meyer, T., Bartmann, U., Hillmer-Vogel, U., & Rüther, E. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.5.603 · Cited by 328
Self-citationAcute pain management: operative or medical procedures and trauma.
Ka, P. (1993) · PubMed · Cited by 325
FISHER, P. L., & DURHAM, R. C. (1999) · Psychological Medicine · doi:10.1017/s0033291799001336 · Cited by 324
Treatment of recent trauma survivors with benzodiazepines: a prospective study.
Gelpin, E., Bonne, O. B., Peri, T., Brandes, D., & Shalev, A. Y. (1996) · PubMed · Cited by 322
Greist, J. H., Marks, I. M., Baer, L., Kobak, K. A., Wenzel, K. W., Hirsch, M. J., Mantle, J. M., & Clary, C. M. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0209 · Cited by 321
Epidemiology of obsessive compulsive disorder.
Rasmussen, S. A., & Eisen, J. L. (1990) · PubMed · Cited by 318
Tollefson, G. D. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950070051010 · Cited by 314
Anderson, I. M., Nutt, D. J., & Deakin, J. F. W. (2000) · Journal of Psychopharmacology · doi:10.1177/026988110001400101 · Cited by 310
Self-citationBrown, T. A., Antony, M. M., & Barlow, D. H. (1995) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.63.3.408 · Cited by 307
Wittchen, H.-U., Carter, R. M., Pfister, H., Montgomery, S. A., & Kessler, R. C. (2000) · International Clinical Psychopharmacology · doi:10.1097/00004850-200015060-00002 · Cited by 299
Ormel, J., Brink, W. V. D., Koeter, M. W. J., Giel, R., Meer, K. V. D., Willige, G. V. D., & Wilmink, F. W. (1990) · Psychological Medicine · doi:10.1017/s0033291700036606 · Cited by 291
Trauma: prevalence, impairment, service use, and cost.
Solomon, S. D., & Davidson, J. R. T. (1997) · PubMed · Cited by 289
Self-citationDEN BOER, J. A., & WESTENBERG, H. G. M. (1988) · International Clinical Psychopharmacology · doi:10.1097/00004850-198801000-00005 · Cited by 288
Gene-Cos, N. (2006) · Psychiatric Bulletin · doi:10.1192/pb.30.9.357-a · Cited by 281
Hohagen, F., Winkelmann, G., Rasche-Räuchle, H., Hand, I., König, A., Münchau, N., Hiss, H., Geiger-Kabisch, C., Käppler, C., Schramm, P., et al. (1998) · British Journal of Psychiatry · doi:10.1192/s0007125000297924 · Cited by 280
Behavioral versus pharmacological treatments of obsessive compulsive disorder: a meta-analysis
Kobak, K. A., Greist, J. H., Jefferson, J. W., Katzelnick, D. J., & Henk, H. J. (1998) · Psychopharmacology · doi:10.1007/s002130050558 · Cited by 276
A preliminary study of lamotrigine for the treatment of posttraumatic stress disorder
Hertzberg, M. A., Butterfield, M. I., Feldman, M. E., Beckham, J. C., Sutherland, S. M., Connor, K. M., & Davidson, J. R. T. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00011-6 · Cited by 271
Self-citationSocial Phobia Symptoms, Subtypes, and Severity: Findings From a Community Survey
Stein, M. B., Torgrud, L. J., & Walker, J. R. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.11.1046 · Cited by 266
Paroxetine in the Treatment of Panic Disorder a Randomised, Double-Blind, Placebo-Controlled Study
Oehrberg, S., Christiansen, P. E., Behnke, K., Borup, A. L., Severin, B., Soegaard, J., Calberg, H., Judge, R., Ohrstrom, J. K., & Manniche, P. M. (1995) · British Journal of Psychiatry · doi:10.1192/bjp.167.3.374 · Cited by 261 · cited 1×
“, 2000) and basic CBT (Ib) (Oehrberg et al., 1995): and buspirone may enhance the short-term efficacy of CBT (Ib) (Cottraux et al.”
BackgroundFeltner, D. E., Crockatt, J. G., Dubovsky, S. J., Cohn, C. K., Shrivastava, R. K., Targum, S. D., Liu-Dumaw, M., Carter, C. M., & Pande, A. C. (2003) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000084032.22282.ff · Cited by 260
Health economics and cost implications of anxiety and other mental disorders in the United States
Rice, D. P., & Miller, L. S. (1998) · British Journal of Psychiatry · doi:10.1192/s0007125000293458 · Cited by 258
Clomipramine, self-exposure and therapist-aided exposure for obsessive–compulsive rituals
Marks, I. M., Lelliott, P., Basoglu, M., Noshirvani, H., Monteiro, W., Cohen, D., & Kasvikis, Y. (1988) · British Journal of Psychiatry · doi:10.1192/bjp.152.4.522 · Cited by 255
Rickels, K., Pollack, M. H., Sheehan, D. V., & Haskins, J. T. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.6.968 · Cited by 252
Denys, D., de Geus, F., van Megen, H. J. G. M., & Westenberg, H. G. M. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0803 · Cited by 248
Occurrence, recognition, and outcome of psychological disorders in primary care
(1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.5.636 · Cited by 245
Clomipramine in obsessive-compulsive disorder
Katz, R. J., DeVeaugh-Geiss, J., & Landau, P. (1990) · Biological Psychiatry · doi:10.1016/0006-3223(90)90408-t · Cited by 245
Epidemiology of obsessive-compulsive disorder: a world view.
Sasson, Y., Zohar, J., Chopra, M., Lustig, M., Iancu, I., & Hendler, T. (1997) · PubMed · Cited by 244
The epidemiology of panic disorder and agoraphobia in Europe
Goodwin, R. D., Faravelli, C., Rosi, S., Cosci, F., Truglia, E., de Graaf, R., & Wittchen, H. U. (2005) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2005.04.006 · Cited by 243
Wagner, K. D., Berard, R., Stein, M. B., Wetherhold, E., Carpenter, D. J., Perera, P., Gee, M., Davy, K., & Machin, A. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.11.1153 · Cited by 240
Treatment of panic disorder via the Internet: a randomized trial of CBT vs. applied relaxation
Carlbring, P., Ekselius, L., & Andersson, G. (2003) · Journal of Behavior Therapy and Experimental Psychiatry · doi:10.1016/s0005-7916(03)00026-0 · Cited by 240
Davidson, J., Pearlstein, T., Londborg, P., Brady, K. T., Rothbaum, B., Bell, J., Maddock, R., Hegel, M. T., & Farfel, G. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.12.1974 · Cited by 228
Self-citationDavidson, J., Baldwin, D., Stein, D. J., Kuper, E., Benattia, I., Ahmed, S., Pedersen, R., & Musgnung, J. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.10.1158 · Cited by 228
Self-citationPande, A. C., Feltner, D. E., Jefferson, J. W., Davidson, J. R. T., Pollack, M., Stein, M. B., Lydiard, R. B., Futterer, R., Robinson, P., Slomkowski, M., et al. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000117423.05703.e7 · Cited by 227
Self-citationThe epidemiology of generalized anxiety disorder in Europe
Lieb, R., Becker, E., & Altamura, C. (2005) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2005.04.010 · Cited by 227
Bower, P., Richards, D. A., & Lovell, K. (2001) · Europe PMC (PubMed Central) · Cited by 226
Double-Blind, Fixed-Dose, Placebo-Controlled Study of Paroxetine in the Treatment of Panic Disorder
Ballenger, J. C., Wheadon, D. E., Steiner, M., Bushnell, W., & Gergel, I. P. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.1.36 · Cited by 220
Why is self-help neglected in the treatment of emotional disorders? A meta-analysis
DEN BOER, P. C. A. M., WIERSMA, D., & VAN DEN BOSCH, R. J. (2004) · Psychological Medicine · doi:10.1017/s003329170300179x · Cited by 220
Social phobia in general health care: an unrecognised undertreated disabling disorder
Weiller, E., Bisserbe, J. C., Boyer, P., Lepine, J. P., & Lecrubier, Y. (1996) · British Journal of Psychiatry · doi:10.1192/bjp.168.2.169 · Cited by 219
Blomhoff, S., Haug, T. T., Hellström, K., Holme, I., Humble, M., Madsbu, H. P., & Wold, J. E. (2001) · British Journal of Psychiatry · doi:10.1192/bjp.179.1.23 · Cited by 218
Ormel, J. (1993) · Archives of General Psychiatry · doi:10.1001/archpsyc.1993.01820220009001 · Cited by 216 · cited 1×
“Studies in primary care suggest approximately 50% significantly improve over 6–16 months (II) (Ormel et al., 1991; Ormel et al., 1993; Ronalds et al., 1997) but complete recovery is relative rare.”
BackgroundZOHAR, A. H., RATZONI, G., PAULS, D. L., APTER, A., BLEICH, A., KRON, S., RAPPAPORT, M., WEIZMAN, A., & COHEN, D. J. (1992) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199211000-00010 · Cited by 214
Factors predicting the clinical course of generalised anxiety disorder
Yonkers, K. A., Dyck, I. R., Warshaw, M., & Keller, M. B. (2000) · British Journal of Psychiatry · doi:10.1192/bjp.176.6.544 · Cited by 213
Overview of Diagnosis and Drug Treatments of Anxiety Disorders
Nutt, D. J. (2005) · CNS Spectrums · doi:10.1017/s1092852900009901 · Cited by 211
Self-citationVAN BALKOM, A. J. L. M., BAKKER, A., SPINHOVEN, P., BLAAUW, B. M. J. W., SMEENK, S., & RUESINK, B. (1997) · The Journal of Nervous & Mental Disease · doi:10.1097/00005053-199708000-00006 · Cited by 211
Evidence-based pharmacotherapy of obsessive–compulsive disorder
Fineberg, N. A., & Gale, T. M. (2005) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145704004675 · Cited by 211
Self-citationMultivariate Meta-Analysis of Controlled Drug Studies for Obsessive-Compulsive Disorder
Ackerman, D. L., & Greenland, S. (2002) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200206000-00012 · Cited by 202
Paroxetine Treatment of Generalized Anxiety Disorder: A Double-Blind, Placebo-Controlled Study
Rickels, K., Zaninelli, R., McCafferty, J., Bellew, K., Iyengar, M., & Sheehan, D. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.4.749 · Cited by 198
Hollander, E., Rossi, N. B., Sood, E., & Pallanti, S. (2003) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145703003730 · Cited by 197 · cited 2×
“Fixed-dose comparator studies provide inconsistent evidence for a dose-response relationship with SSRIs, higher doses being associated with greater efficacy in some (Ib) (Montgomery et al., 1993; Wheadon et al., 1993; Hollander et al., 2003) but not all evaluations (Ib) (Tollefson et al.”
BackgroundGoldberg, D. P., & Bridges, K. W. (1987) · PubMed · Cited by 192
The twelve-month outcome of patients with neurotic illness in general practice
Mann, A. H., Jenkins, R., & Belsey, E. (1981) · Psychological Medicine · doi:10.1017/s0033291700052855 · Cited by 191
Ballenger, J. C., Davidson, J. R. T., Lecrubier, Y., Nutt, D. J., Marshall, R. D., Nemeroff, C. B., Shalev, A. Y., & Yehuda, R. (2004) · PubMed · Cited by 188
Self-citationMontgomery, S. A., Kasper, S., Stein, D. J., Hedegaard, K. B., & Lemming, O. M. (2001) · International Clinical Psychopharmacology · doi:10.1097/00004850-200103000-00002 · Cited by 187
Roy-Byrne, P. P., Stein, M. B., Russo, J., Mercier, E., Thomas, R., McQuaid, J., Katon, W. J., Craske, M. G., Bystritsky, A., & Sherbourne, C. D. (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n0713 · Cited by 186
A comparison of bibliotherapy and group therapy in the treatment of panic disorder.
Lidren, D. M., Watkins, P. L., Gould, R. A., & Clum, G. A. (1994) · Journal of Consulting and Clinical Psychology · doi:10.1037//0022-006x.62.4.865 · Cited by 184
The economic consequences of social phobia
Patel, A., Knapp, M., Henderson, J., & Baldwin, D. (2002) · Journal of Affective Disorders · doi:10.1016/s0165-0327(00)00323-2 · Cited by 180
Self-citationMental disorders in primary care
Wittchen, H.-U., Mühlig, S., & Beesdo, K. (2003) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2003.5.2/huwittchen · Cited by 180
Otto, M. W., Pollack, M. H., Gould, R. A., Worthington, J. J., McArdle, E. T., Rosenbaum, J. F., & Heimberg, R. G. (2000) · Journal of Anxiety Disorders · doi:10.1016/s0887-6185(00)00027-x · Cited by 175
Allgulander, C., Hackett, D., & Salinas, E. (2001) · British Journal of Psychiatry · doi:10.1192/bjp.179.1.15 · Cited by 175
Montgomery, S. (1993) · European Neuropsychopharmacology · doi:10.1016/0924-977x(93)90266-o · Cited by 172
Katon, W. J., Roy-Byrne, P., Russo, J., & Cowley, D. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.12.1098 · Cited by 171
Lingford-Hughes, A. R., Welch, S., & Nutt, D. J. (2004) · Journal of Psychopharmacology · doi:10.1177/026988110401800321 · Cited by 167
Self-citationBandelow, B., Zohar, J., Hollander, E., Kasper, S., Möller, H.-J., & WFSBP Task Force on Treatment Guide (2002) · The World Journal of Biological Psychiatry · doi:10.3109/15622970209150621 · Cited by 167
Self-citationCost of anxiety disorders in Europe
Andlin‐Sobocki, P., & Wittchen, H. ‐. (2005) · European Journal of Neurology · doi:10.1111/j.1468-1331.2005.01196.x · Cited by 165
Lader, M., Stender, K., Bürger, V., & Nil, R. (2004) · Depression and Anxiety · doi:10.1002/da.20014 · Cited by 163 · cited 3×
“Double-blind studies indicate that continuing SSRI or SNRI treatment from 12 weeks to 24 weeks is associated with an increase in overall treatment response rates (Ib) (Stein et al., 2003; Lader et al., 2004; Stein et al., 2005).”
BackgroundInfluentialLow-Dose Risperidone as Adjunctive Therapy for Irritable Aggression in Posttraumatic Stress Disorder
Monnelly, E. P., Ciraulo, D. A., Knapp, C., & Keane, T. (2003) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200304000-00012 · Cited by 163
Hamner, M. B., Faldowski, R. A., Ulmer, H. G., Frueh, B. C., Huber, M. G., & Arana, G. W. (2003) · International Clinical Psychopharmacology · doi:10.1097/00004850-200301000-00001 · Cited by 162
Otto, M. W., Tuby, K. S., Gould, R. A., McLean, R. Y. S., & Pollack, M. H. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.12.1989 · Cited by 162
McDougle, C. J., Price, L. H., Goodman, W. K., Charney, D. S., & Heninger, G. R. (1991) · PubMed · Cited by 161
Post-treatment effects of exposure therapy and clomipramine in obsessive–compulsive disorder
Simpson, H. B., Liebowitz, M. R., Foa, E. B., Kozak, M. J., Schmidt, A. B., Rowan, V., Petkova, E., Kjernisted, K., Huppert, J. D., Franklin, M. E., et al. (2004) · Depression and Anxiety · doi:10.1002/da.20003 · Cited by 161
Venlafaxine Extended Release vs Placebo and Paroxetine in Social Anxiety Disorder
Liebowitz, M. R., Gelenberg, A. J., & Munjack, D. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.2.190 · Cited by 160
Katz, I. R., Reynolds, C. F., Alexopoulos, G. S., & Hackett, D. (2002) · Journal of the American Geriatrics Society · doi:10.1046/j.1532-5415.2002.50003.x · Cited by 158
Hollander, E., Allen, A., Steiner, M., Wheadon, D. E., Oakes, R., Burnham, D. B., & Paroxetine OCD Study Group (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0919 · Cited by 156
How Psychiatrists Can Build New Therapies for Impotence: (Brainstorms)
Stahl, S. M. (1998) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v59n0201 · Cited by 154
Comorbid anxiety and mood disorders among persons with social anxiety disorder
Erwin, B. A., Heimberg, R. G., Juster, H., & Mindlin, M. (2002) · Behaviour Research and Therapy · doi:10.1016/s0005-7967(00)00114-5 · Cited by 153
Shannahoff-Khalsa, D. S., Ray, L. E., Levine, S., Gallen, C. C., Schwartz, B. J., & Sidorowich, J. J. (1999) · CNS Spectrums · doi:10.1017/s1092852900006805 · Cited by 152
Exposure therapy and sertraline in social phobia: 1-year follow-up of a randomised controlled trial
Haug, T. T., Blomhoff, S., Hellstrøm, K., Holme, I., Humble, M., Madsbu, H. P., & Wold, J. E. (2003) · British Journal of Psychiatry · doi:10.1192/bjp.182.4.312 · Cited by 151
Atmaca, M., Kuloglu, M., Tezcan, E., & Gecici, O. (2002) · International Clinical Psychopharmacology · doi:10.1097/00004850-200205000-00004 · Cited by 149
(1997) · PubMed · Cited by 149
Möller, H.-J., Volz, H.-P., Reimann, I. W., & Stoll, K.-D. (2001) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200102000-00011 · Cited by 147
Onset of Panic Disorder With Agoraphobia: Toward an Integrated Model
Lelliott, P. (1989) · Archives of General Psychiatry · doi:10.1001/archpsyc.1989.01810110042006 · Cited by 145
Effectiveness of complementary and self‐help treatments for anxiety disorders
Jorm, A. F., Christensen, H., Griffiths, K. M., Parslow, R. A., Rodgers, B., & Blewitt, K. A. (2004) · Medical Journal of Australia · doi:10.5694/j.1326-5377.2004.tb06352.x · Cited by 144
Patient perspectives on once-weekly fluoxetine.
Judge, R. (2001) · PubMed · Cited by 144
WCA Recommendations for the Long-Term Treatment of Obsessive-Compulsive Disorder in Adults
Greist, J. H., Bandelow, B., Hollander, E., Marazziti, D., Montgomery, S. A., Nutt, D. J., Okasha, A., Swinson, R. P., & Zohar, J. (2003) · CNS Spectrums · doi:10.1017/s1092852900006908 · Cited by 143
Self-citationLlorca, P.-M., Spadone, C., Sol, O., Danniau, A., Bougerol, T., Corruble, E., Faruch, M., Macher, J.-P., Sermet, E., & Servant, D. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n1112 · Cited by 142
Obsessive-compulsive syndromes and disorders
Angst, J., Gamma, A., Endrass, J., Hantouche, E. G., Goodwin, R., Ajdacic‐Gross, V., Eich, D., & Wulf Rössler, A. (2005) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-005-0576-8 · Cited by 142
A Meta-analytic Review of the Efficacy of Drug Treatment in Generalized Anxiety Disorder
Mitte, K., Noack, P., Steil, R., & Hautzinger, M. (2005) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000155821.74832.f9 · Cited by 140
Versiani, M., Cassano, G., Perugi, G., Benedetti, A., Mastalli, L., Nardi, A., & Savino, M. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0107 · Cited by 140
Long‐term evaluation of paroxetine, clomipramine and placebo in panic disorder
Lecrubier, Y., Judge, R., & The Collaborative Paroxetine Panic Study Investigators (1997) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1997.tb00389.x · Cited by 139
Stahl, S. M., Gergel, I., & Li, D. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n1107 · Cited by 139
Efficacy of Sertraline in a 12-Week Trial for Generalized Anxiety Disorder
Allgulander, C., Dahl, A. A., Austin, C., Morris, P. L. P., Sogaard, J. A., Fayyad, R., Kutcher, S. P., & Clary, C. M. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.9.1642 · Cited by 139
Erzegovesi, S., Guglielmo, E., Siliprandi, F., & Bellodi, L. (2004) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2004.04.004 · Cited by 138
Londborg, P. D., Hegel, M. T., Goldstein, S., Goldstein, D., Himmelhoch, J. M., Maddock, R., Patterson, W. M., Rausch, J., & Farfel, G. M. (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n0503 · Cited by 136
Anxiety and anxiety disorders in the old and very old—Results from the Berlin aging study (BASE)
Schaub, R., & LINDEN, M. E. L. V. D. (2000) · Comprehensive Psychiatry · doi:10.1016/s0010-440x(00)80008-5 · Cited by 136
Outcome of anxiety and depressive disorders in primary care
Ronalds, C., Creed, F., Stone, K., Webb, S., & Tomenson, B. (1997) · British Journal of Psychiatry · doi:10.1192/bjp.171.5.427 · Cited by 136
LADER, M. H., & Scotto, J. (1998) · Psychopharmacology · doi:10.1007/s002130050731 · Cited by 135
McDOUGLE, C. J., PRICE, L. H., GOODMAN, W. K., CHARNEY, D. S., & HENINGER, G. R. (1991) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199106000-00005 · Cited by 134
Greist, J. H., Jefferson, J. W., Kobak, K. A., Chouinard, G., DuBoff, E., Halaris, A., Kim, S. W., Koran, L., Liebowtiz, M. R., Lydiard, B., et al. (1995) · International Clinical Psychopharmacology · doi:10.1097/00004850-199506000-00001 · Cited by 133
Fluoxetine v. placebo in prevention of relapse in post-traumatic stress disorder
Martenyi, F., Brown, E. B., Zhang, H., Koke, S. C., & Prakash, A. (2002) · British Journal of Psychiatry · doi:10.1192/bjp.181.4.315 · Cited by 132
Weiller, E., Bisserbe, J.-C., Maier, W., & Lecrubier, Y. (1998) · British Journal of Psychiatry · doi:10.1192/s0007125000293471 · Cited by 132
A European perspective on social anxiety disorder
Lecrubier, Y., Wittchen, H. U., Faravelli, C., Bobes, J., Patel, A., & Knapp, M. (2000) · European Psychiatry · doi:10.1016/s0924-9338(00)00216-9 · Cited by 130
Self-citationEvidence-based pharmacotherapy of Generalized Anxiety Disorder
Baldwin, D. S., & Polkinghorn, C. (2005) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145704004870 · Cited by 129
Self-citationEfficacy and Tolerability of Paroxetine for the Long-Term Treatment of Generalized Anxiety Disorder
Stocchi, F., Nordera, G., Jokinen, R. H., Lepola, U. M., Hewett, K., Bryson, H., Iyengar, M. K., & Paroxetine Generalized Anxiety Disorder Study Team (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0305 · Cited by 128
Hoehn-Saric, R., Ninan, P., Black, D. W., Stahl, S., Greist, J. H., Lydiard, B., McElroy, S., Zajecka, J., Chapman, D., Clary, C., et al. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.1.76 · Cited by 126
Michelson, D., Lydiard, R. B., Pollack, M. H., Tamura, R. N., Hoog, S. L., Tepner, R., Demitrack, M. A., Tollefson, G. D., & the Fluoxetine Panic Disorder Study Group (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.11.1570 · Cited by 123
Lenze, E. J., Mulsant, B. H., Shear, M. K., Dew, M. A., Miller, M. D., Pollock, B. G., Houck, P., Tracey, B., & Reynolds, C. F. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.1.146 · Cited by 121
(1993) · American Journal of Psychiatry · doi:10.1176/ajp.150.5.819 · Cited by 120
Stein, M. B., Pollack, M. H., Bystritsky, A., Kelsey, J. E., & Mangano, R. M. (2004) · Psychopharmacology · doi:10.1007/s00213-004-1957-9 · Cited by 117
Severity of depressive symptoms and response to antidepressants and placebo in antidepressant trials
Khan, A., Brodhead, A. E., Kolts, R. L., & Brown, W. A. (2004) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2004.06.005 · Cited by 117
Dannon, P. N., Sasson, Y., Hirschmann, S., Iancu, I., Grunhaus, L. J., & Zohar, J. (2000) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(00)00065-1 · Cited by 116
Liebowitz, M. R., Stein, M. B., Tancer, M., Carpenter, D., Oakes, R., & Pitts, C. D. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0113 · Cited by 116
Comparison of the General Health Questionnaire and the Hospital Anxiety and Depression Scale
Lewis, G., & Wessely, S. (1990) · British Journal of Psychiatry · doi:10.1192/bjp.157.6.860 · Cited by 116
PIGOTT, T. A., PATO, M. T., L??HEUREUX, F., HILL, J. L., GROVER, G. N., BERNSTEIN, S. E., & MURPHY, D. L. (1991) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199108000-00004 · Cited by 115
Cost of anxiety disorders: Impact of comorbidity
Souêtre, E., Lozet, H., Cimarosti, I., Martin, P., CHIGNON, J. M., Adès, J., Tignol, J.-P., & DARCOURT, G. (1994) · Journal of Psychosomatic Research · doi:10.1016/0022-3999(94)90145-7 · Cited by 113
PIGOTT, T. A., LʼHEUREUX, F., HILL, J. L., BIHARI, K., BERNSTEIN, S. E., & MURPHY, D. L. (1992) · Current Opinion in Cardiology · doi:10.1097/00001573-199202000-00003 · Cited by 113
Allgulander, C., Mangano, R., Zhang, J., Dahl, A. A., Lepola, U., Sjödin, I., & Emilien, G. (2004) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.602 · Cited by 111
Silverstone, P. H., & Salinas, E. (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n07a04 · Cited by 111
One-session group therapy of spider phobia: Direct versus indirect treatments
Öst, L., Ferebee, I., & Furmark, T. (1997) · Behaviour Research and Therapy · doi:10.1016/s0005-7967(97)00028-4 · Cited by 111
A Controlled, Prospective, 1-Year Trial of Citalopram in the Treatment of Panic Disorder
Lepola, U. M., Wade, A. G., Leinonen, E. V., Koponen, H. J., Frazer, J., Sjodin, I., Penttinen, J. T., Pedersen, T., & Lehto, H. J. (1998) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v59n1006 · Cited by 111
Fallon, B. A., Liebowitz, M. R., Campeas, R., Schneier, F. R., Marshall, R., Davies, S., Goetz, D., & Klein, D. F. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.10.918 · Cited by 111
ISSAKIDIS, C., SANDERSON, K., CORRY, J., ANDREWS, G., & LAPSLEY, H. (2004) · Psychological Medicine · doi:10.1017/s003329170300881x · Cited by 110 · cited 1×
“In general, economic models suggest that evidence-based treatment of anxiety disorders would produce greater population health gain at a similar cost to current care (II) (e.g. Patel et al., 2002; Issakidis et al., 2004; NICE, 2005) – consequences which are likely to be seen as a cost-effective use of resources.”
BackgroundBielski, R. J., Bose, A., & Chang, C.-C. (2005) · Annals of Clinical Psychiatry · doi:10.1080/10401230590932326 · Cited by 109
Venlafaxine in social phobia: a study in selective serotonin reuptake inhibitor non-responders
Altamura, A. C., Pioli, R., Vitto, M., & Mannu, P. (1999) · International Clinical Psychopharmacology · doi:10.1097/00004850-199907000-00006 · Cited by 109
MUSKIN, P. R., & FYER, A. J. (1981) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-198103000-00007 · Cited by 109
Cognitive behavior therapy for treatment-refractory panic disorder.
Pollack, M. H., Otto, M. W., Kaspi, S. P., Hammerness, P. G., & Rosenbaum, J. F. (1994) · PubMed · Cited by 108
(1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.6.758 · Cited by 107
Pharmacotherapy for social anxiety disorder
Stein, D. J., Ipser, J. C., & van Balkom, A. J. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001206.pub2 · Cited by 102
Pharmacological Treatment of Agoraphobia: Imipramine versus Imipramine with Programmed Practice
Mavissakalian, M., Michelson, L., & Dealy, R. S. (1983) · British Journal of Psychiatry · doi:10.1192/bjp.143.4.348 · Cited by 102
Buspirone augmentation of selective serotonin reuptake inhibitors (SSRIs) in social phobia
Ameringen, M. V., Mancini, C., & Wilson, C. (1996) · Journal of Affective Disorders · doi:10.1016/0165-0327(96)00030-4 · Cited by 99
Fux, M., Benjamin, J., & Belmaker, R. H. (1999) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145799001546 · Cited by 97
Cottraux, J. A., Mollard, E., Bouvard, M. A., & Marks, I. M. (1993) · Psychiatry Research · doi:10.1016/0165-1781(93)90030-k · Cited by 96
Treatment of Generalized Anxiety Disorder
(2013) · Cognitive Coping Therapy · doi:10.4324/9780203782668-12 · Cited by 96
Costs and Offset Effect in Panic Disorders
Salvador-Carulla, L., Seguí, J., Fernández-Cano, P., & Canet, J. (1995) · British Journal of Psychiatry · doi:10.1192/s0007125000293367 · Cited by 93
Epidemiology of social phobia: a clinical approach
Faravelli, C., Zucchi, T., Viviani, B., Salmoria, R., Perone, A., Paionni, A., Scarpato, A., Vigliaturo, D., Rosi, S., D’adamo, D., et al. (2000) · European Psychiatry · doi:10.1016/s0924-9338(00)00215-7 · Cited by 93
WCA Recommendations for the Long-Term Treatment of Generalized Anxiety Disorder
Allgulander, C., Bandelow, B., Hollander, E., Montgomery, S. A., Nutt, D. J., Okasha, A., Pollack, M. H., Stein, D. J., & Swinson, R. P. (2003) · CNS Spectrums · doi:10.1017/s1092852900006945 · Cited by 93
Self-citationDURHAM, R. C., CHAMBERS, J. A., MACDONALD, R. R., POWER, K. G., & MAJOR, K. (2003) · Psychological Medicine · doi:10.1017/s0033291702007079 · Cited by 92
Stein, M. B., Sareen, J., Hami, S., & Chao, J. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.10.1725 · Cited by 91
Mirtazapine versus fluoxetine in the treatment of panic disorder
Ribeiro, L., Busnello, J. V., Kauer-Sant'Anna, M., Madruga, M., Quevedo, J., Busnello, E. A. D., & Kapczinski, F. (2001) · Brazilian Journal of Medical and Biological Research · doi:10.1590/s0100-879x2001001000010 · Cited by 91
Follow-Up on the Treatment of Panic Disorder With or Without Agoraphobia: A Quantitative Review
BAKKER, A., van BALKOM, A. J. L. M., SPINHOVEN, P., BLAAUW, B. M. J. W., & van DYCK, R. (1998) · The Journal of Nervous & Mental Disease · doi:10.1097/00005053-199807000-00005 · Cited by 89
Hirschmann, S., Dannon, P. N., Iancu, I., Dolberg, O. T., Zohar, J., & Grunhaus, L. (2000) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200010000-00011 · Cited by 89 · cited 1×
“, 2002), and augmentation of fluoxetine with pindolol was superior to continued monotherapy with fluoxetine (Hirschmann et al., 2000).”
Background(1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.10.1438 · Cited by 88
Stein, D. J., Stein, M. B., Pitts, C. D., Kumar, R., & Hunter, B. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0211 · Cited by 88
Skinner, R. D., Rasco, L., Fitzgerald, J., Karson, C. N., Matthew, M., Williams, D. K., & García‐Rill, E. (1999) · Depression and Anxiety · doi:10.1002/(sici)1520-6394(1999)9:3<122::aid-da4>3.0.co;2-m · Cited by 88
Heldt, E., Manfro, G. G., Kipper, L., Blaya, C., Maltz, S., Isolan, L., Hirakata, V. N., & Otto, M. W. (2003) · Psychotherapy and Psychosomatics · doi:10.1159/000067188 · Cited by 87
Research works printed but not linked: 39
- Allgulander C, ADAA meeting
- Baldwin D S, 1998, J Clin Psychiatry, 59, S39
- Ballenger J C, 1998, J Clin Psychiatry, 59, 47
- Ballenger J C, 1998, J Clin Psychiatry, 59, 54
- Ballenger J C, 2001, J Clin Psychiatry, 62, 53
- Ballenger J C, 2004, J Clin Psychiatry, 65, 55
- Bielski R J, 42nd Annual Meeting of the American College of Neuropsychopharmacology
- Bower P, 2001, Br J Gen Pract, 51, 838
- Committee on Safety of Medicines, 2004, Safety of selective serotonin reuptake inhibitor antidepressants
- Davidson J R, American College of Neuropsychopharmacology
- Den Boer J A, 1998, J Clin Psychiatry, 59, 30
- Dowell A C, 1990, Br J Gen Pract, 40, 27
- Durham R C, Long-term outcome of cognitive behavior therapy clinical trials in central Scotland
- Friedman M J, 2000, Effective Treatments for PTSD: Practice Guidelines from the International Society for Stress Studies, 84
- Gelpin E, 1996, J Clin Psychiatry, 57, 390
- Goldberg D, 1987, J R Coll Gen Pract, 37, 15
- Jorm A F, 2004, Med J Aust, 181, S29
- 10.1037/0022-006x.62.4.865 · DOI · Paper page
- 10.1002/(sici)1520-6394(1999)10:3<89::aid-da1>3.0.co;2-5 · doi:10.1002/(sici)1520-6394(1999)10:3<89::aid-da1>3.0.co;2-5
- Meibach R C, 1987, J Clin Psychiatry, 84, 355
- Mendels J, 1986, J Clin Psychiatry, 47, 170
- National Institute for Clinical Excellence, 2004, Depression. Management of depression in primary and secondary care
- National Institute for Clinical Excellence, 2005, Post-traumatic stress disorder. The management of PTSD in adults and children in primary and secondary care
- Parkerson G R Jr, 1997, Fam Med, 29, 177
- Pollack M H, American College of Neuropsychopharmacology
- Pollack M H, 1994, J Clin Psychiatry, 55, 200
- Power K G, 1990, Br J Gen Pract, 40, 289
- Rasmussen S A, 1990, J Clin Psychiatry, 51, 10
- Royal College of Psychiatrists, 2005, Benzodiazepines: risks, benefits or dependence. A re-evaluation
- Sasson Y, 1997, J Clin Psychiatry, 58, 7
- Schatzberg A F, 1997, J Clin Psychiatry, 58, 5
- Stein D J, 2004, Cochrane Library
- Tollefson G D, 1994, J Clin Psychiatry, 55, 69
- 10.1002/(sici)1099-0879(199809)5:3<126::aid-cpp153>3.0.co;2-h · doi:10.1002/(sici)1099-0879(199809)5:3<126::aid-cpp153>3.0.co;2-h
- Weissman M M, 1994, J Clin Psychiatry, 55, 5
- Wheadon D, Annual Meeting of the American College of Neuro psychopharmacology
- Wittchen H U, 2002, J Clin Psychiatry, 63, 24
- World Health Organization, 1992, The ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines
- World Health Organization, 2004, WHO Guide to Mental and Neurological Health in Primary Care
Cited by
Phasic vs Sustained Fear in Rats and Humans: Role of the Extended Amygdala in Fear vs Anxiety
Davis, M., Walker, D. L., Miles, L., & Grillon, C. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.109 · Cited by 1,513
Comorbidity of anxiety and depression in children and adolescents: 20 years after
Cummings, C. M., Caporino, N. E., & Kendall, P. C. (2014) · Psychological Bulletin · doi:10.1037/a0034733 · Cited by 1,028
“SSRIs are frequently prescribed for child/adolescent anxiety disorders (Baldwin et al., 2005) and depression (Birmaher & Brent, 2002).”
Anderson, I., Ferrier, I., Baldwin, R., Cowen, P., Howard, L., Lewis, G., Matthews, K., McAllister-Williams, R., Peveler, R., Scott, J., et al. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881107088441 · Cited by 908
Self-citationBandelow, B., Zohar, J., Hollander, E., Kasper, S., Möller, H.-J., WFSBP TASK FORCE ON TREATMENT GUIDE, Bandelow, B., Zohar, J., Hollander, E., Kasper, S., et al. (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970802465807 · Cited by 854
Self-citationInternet Addiction: Definition, Assessment, Epidemiology and??Clinical Management
Shaw, M., & Black, D. W. (2008) · CNS Drugs · doi:10.2165/00023210-200822050-00001 · Cited by 807
Metadata
- Authors
- Baldwin, D. S., Anderson, I. M., Nutt, D. J., Bandelow, B., Bond, A., Davidson, J. R. T., den Boer, J. A., Fineberg, N. A., Knapp, M., Scott, J., & Wittchen, H. U.
- Affiliations
- University of Southampton (GB)
- University of Manchester (GB)
- University of Bristol (GB)
- University of Göttingen (DE)
- King's College London (GB)
- Duke Medical Center (US)
- School of Behavioral and Cognitive Neurosciences, University Medical Center Groningen, Groningen, the Netherlands
- University of Hertfordshire (GB)
- Technical University of Dresden and Max Planck Institute of Psychiatry, Munich, Germany
- Corresponding author
- Baldwin, David S.
- ORCID
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2005-11
- Volume
- 19
- Issue
- 6
- Pages
- 567-596
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W2151852296
- Cited by
- 617
- References
- 273
- Citations by year
- 2026: 7 · 2025: 8 · 2024: 13 · 2023: 6 · 2022: 9 · 2021: 21 · 2020: 22 · 2019: 22 · 2018: 26 · 2017: 24 · 2016: 22 · 2015: 29 · 2014: 53 · 2013: 47 · 2012: 53
- FWCI
- 45.54
- Type
- journal article
- Language
- en
- Open access
- green
- tud.qucosa.de
- Licence
- other-oa
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Journal of Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion)
- Max Planck Institute for Plasma Physics (submittedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- Research Portal (King's College London) (submittedVersion)
- Qucosa (Saxon State and University Library Dresden) (submittedVersion, other-oa)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Topics
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Keywords
- anxiety disorders, pharmacotherapy, psychopharmacology, treatment guidelines, evidence-based recommendations, acute treatment, relapse prevention, treatment-resistant anxiety, clinical decision-making
- MeSH terms
- Adolescent, Adult, Aged, Antidepressive Agents, Anxiety Disorders, Behavior Therapy, Breast Feeding, Child, Preschool, Combined Modality Therapy, Female, Humans, Male, Middle Aged, Pregnancy, Psychotropic Drugs, Anti-Anxiety Agents, Treatment Outcome, Evidence-Based Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.